Abstract Details

Title The Economic Burden of Spinal Muscular Atrophy Patients in a Commercially-Insured Population in the United States

Topic Child Neurology and Developmental Neurology

Presentation(s) P1 - Poster Session 1 (5:30 PM-6:30 PM)

Poster/Presentation
Number 7-054

Objective To assess the economic burden associated with the treatment of Spinal Muscular Atrophy (SMA) patients in the US.

Background In addition to its high psychosocial impact, SMA can place a considerable economic burden on patients and their caregivers. However, despite the high clinical burden, limited information exists on the economic burden of the disease.

Design/Methods A retrospective analysis of Truven MarketScan^® Commercial and Medicare Supplemental Databases was conducted (January 2012 – March 2017) to identify SMA patients by ≥2 diagnosis codes (ICD-9: 335.0, 335.1x; ICD-10: G12.0, G12.1, G12.8, G12.9) on inpatient or outpatient medical claims >30 days apart. Patients were categorized in age groups, based on the index date of first claim (<2 years, 2-18 years, and >18 years). Patients were followed from index date until the end of continuous enrollment, or the end of the study period, whichever occurred earlier. All-cause and disease-specific healthcare resource utilization, and associated direct costs were captured from the claims databases, and were annualized. Costs were adjusted to 2017 US dollars.

Results A total of 1,120 patients were included. Overall, 60.6% patients visited a neurologist or pulmonologist, 73.5% utilized home health services, 51.8% had emergency room visits, and 41.1% were hospitalized. Procedures with the highest utilization across the cohort were gastrostomy (21.5%) and tracheostomy (17.8%). Durable medical equipment with frequent use included CPAP/BiPAP (28.1%), oxygen machines (25.1%), and suction devices (23.0%). Utilization of healthcare and supportive care resources was higher among pediatric patients. Mean (SD) all-cause annual direct healthcare costs were $65,490 ($135,268), and were highest for SMA patients aged <2 years ($159,227 [$313,121]). Outpatient medical services accounted for 52.8% of costs across the study cohort. Disease-specific costs accounted for 49.4% of total costs, which on average (SD) totaled $32,332 ($93,687).

Conclusions In a commercially-insured population, SMA patients had high economic burden driven by outpatient medical spend.

Authors/Disclosures
PRESENTER	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Kristen Johnson, PhD (Novartis)	No disclosure on file

��ɫ��

��ɫ��